Disease · MONDO_0005016
Comparisons in its trials44
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 44
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death. | 350 of 3,686 | 395 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: All-cause Hospitalization | 1,573 of 3,686 | 1,605 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: deaths from any cause | 339 of 3,686 | 383 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: All-cause Mortality | 333 of 3,686 | 370 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death | 108 of 3,686 | 139 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure. | 458 of 3,686 | 519 of 3,666 | 7,352 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: serious adverse events | 1,158 of 3,683 | 1,215 of 3,658 | 7,341 | NCT02545049 | Trial comparisons |
| Finerenone vs Placebo: All-cause Mortality | 219 of 2,833 | 244 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death | 504 of 2,833 | 600 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure | 367 of 2,833 | 420 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: All-cause Hospitalization | 1,263 of 2,833 | 1,321 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death | 252 of 2,833 | 326 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: deaths from any cause | 222 of 2,833 | 250 of 2,841 | 5,674 | NCT02540993 | Trial comparisons |
| Finerenone vs Placebo: serious adverse events | 902 of 2,827 | 971 of 2,831 | 5,658 | NCT02540993 | Trial comparisons |
| Canagliflozin 100 mg vs Placebo: deaths from any cause | 164 of 2,200 | 193 of 2,197 | 4,397 | NCT02065791 | Trial comparisons |
| Canagliflozin 100 mg vs Placebo: serious adverse events | 737 of 2,200 | 806 of 2,197 | 4,397 | NCT02065791 | Trial comparisons |
| Intent-to-Treat (ITT) Atrasentan vs Intent-to-Treat Placebo: Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled) | 152 of 1,834 | 192 of 1,834 | 3,668 | NCT01858532 | Trial comparisons |
Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 79 of 1,325 | 105 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 78 of 1,325 | 88 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 147 of 1,325 | 172 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005016/comparisons